Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17619719 | 1.00 | L3MBTL3 (0.48) | L3MBTL3L3MBTL1HTR6MBTD1CYP2D6 | |
| SCHEMBL14098366 | 0.97 | — | — | |
| SCHEMBL29058882 | 0.94 | HTR6 (0.50) | L3MBTL3L3MBTL1HTR6MBTD1CYP2D6 | |
| SCHEMBL60131 | 0.93 | HTR6 (0.54) | L3MBTL3L3MBTL1HTR6MBTD1CYP2D6 | |
| SCHEMBL22216666 | 0.93 | HTR6 (0.54) | L3MBTL3L3MBTL1HTR6MBTD1CYP2D6 | |
| SCHEMBL24782761 | 0.93 | HTR6 (0.54) | L3MBTL3L3MBTL1HTR6MBTD1CYP2D6 | |
| SCHEMBL21057384 | 0.93 | HTR6 (0.54) | L3MBTL3L3MBTL1HTR6MBTD1CYP2D6 | |
| SCHEMBL21057351 | 0.93 | HTR6 (0.54) | L3MBTL3L3MBTL1HTR6MBTD1CYP2D6 | |
| SCHEMBL1828721 | 0.93 | HTR6 (0.54) | L3MBTL3L3MBTL1HTR6MBTD1CYP2D6 | |
| SCHEMBL728754 | 0.93 | HTR6 (0.54) | L3MBTL3L3MBTL1HTR6MBTD1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124516-A1 | COMPOUND HAVING AKT KINASE-DEGRADING ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 南京正大天晴制药有限公司 | 2025-06-19 | — | — | WO | claimed |
| CN-118525026-A | Compound for inhibiting or degrading HPK1 kinase and application thereof in medicine | 西藏海思科制药有限公司 | 2024-08-20 | — | — | CN | claimed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| WO-2023166349-A2 | PHENYLUREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 杭州百诚医药科技股份有限公司 | 2023-09-07 | — | — | WO | claimed |
| CN-116554147-A | Pyrazole derivative, composition and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-08-08 | — | — | CN | claimed |
| WO-2023143384-A1 | COMPOUND FOR INHIBITING OR DEGRADING HPK1 KINASE AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2023-08-03 | — | — | WO | claimed |
| CN-116375742-A | Azaaromatic ring derivative, composition and pharmaceutical application thereof | 海思科医药集团股份有限公司 | 2023-07-04 | — | — | CN | claimed |
| WO-2023109892-A1 | COMPOUND FOR INHIBITING OR DEGRADING BRD9, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 海思科医药集团股份有限公司 | 2023-06-22 | — | — | WO | claimed |
| CN-116134028-A | Compound capable of degrading BTK kinase, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-05-16 | — | — | CN | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| CN-114874286-A | Compound for degrading BTK kinase, pharmaceutical composition and pharmaceutical application thereof | 四川海思科制药有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-114805199-A | Benzene ring derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114507235-A | Compound capable of degrading BTK kinase, preparation method and pharmaceutical application thereof | 海思科医药集团股份有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-114437035-A | Compound for inhibiting and degrading IRAK4, pharmaceutical composition and pharmaceutical application thereof | 海思科医药集团股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-113387931-A | Compound capable of inhibiting or degrading protein kinase, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-09-14 | — | — | CN | claimed |
| CN-113292536-A | Compound capable of degrading Bcr-Abl or PARP and preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-08-24 | — | — | CN | claimed |
| CN-112390785-A | BET family bromodomain inhibitor ring derivative, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-02-23 | — | — | CN | claimed |
| WO-2025124516-A1 | COMPOUND HAVING AKT KINASE-DEGRADING ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 南京正大天晴制药有限公司 | 2025-06-19 | — | — | WO | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| WO-2009047264-A1 | SPIROPYRROLIDINES AND THEIR USE AGAINST HCV AND HIV INFECTION | NOVARTIS AG (CH) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | L3MBTL3 1423/4885L3MBTL1 1501/4885HTR6 3197/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL3 1217/4885L3MBTL1 849/4885HTR6 3425/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | L3MBTL3 1423/4885L3MBTL1 1501/4885HTR6 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.